Abstract submission is now open. The approved abstracts will be published in a collection in the regular issue of Human Gene Therapy. We warmly welcome rare diseases researchers to submit abstracts!
Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies. HGT has an Impact Factor of 4.0.
Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
The abstract submission guidelines are as follows:
All abstracts must be written in English, and the abstract text should not exceed 250 words.
Please follow the format outlined in the attached template, which includes the title, author(s), affiliation(s), corresponding author's email, abstract text, and keywords.
The abstract text should be written in a single paragraph. It should concisely state the research objectives, methods, key findings, and implications. Do not include citations, tables, or figures in the abstract.
Submissions must be in Word format, and the file name must match the title of the abstract.
Authors are solely responsible for the content of their submissions. Abstracts that do not meet the formatting requirements, contain errors, or do not fall within the scope of the topics listed below will not be accepted.
Abstract submission topics includes:
Basic and clinical advances in gene therapy
Delivery systems
Cell therapy
Immunotherapy
Clinical genome editing
Small nucleic acid therapeutics, including RNAi
Clinical trials (including confirmatory or negative results)
Improvements in vector developments
Animal models
Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products
Clinical protocols
Commercial development of gene and cell therapy products
Submission Email: HRSC@hope4rare.org.cn (The email subject line should include “Abstract Submission”)
Abstract Submission Deadline: May 10, 2026.
Notification of Accepted Abstracts: By May 31, 2026.
Abstract Template attached:
Abstract Template for HRSC2026.docx
即日起，大会开启摘要投稿，审核通过的摘要将以合辑形式发表在Human Gene Therapy的正刊中，投稿人有机会在大会现场的壁报专区进行展示，欢迎罕见病科研工作者踊跃投稿。
Human Gene Therapy（HGT）是涵盖基因疗法各个方面的最重要的多学科期刊，刊登DNA、RNA、细胞和免疫疗法的重要进展，并验证研究和新技术的最新进展。该期刊的影响因子为4.0。
HGT创刊于1990年，为发表科学和临床研究成果（包括伦理、法规、监管、社会和商业议题）提供了一个享有盛誉的平台，推动治疗程序的发展和进步，改善患者的治疗效果，并最终治愈疾病。
在2024年5月举办的第二届大会中，最终有55篇摘要被大会接收，并于2025年4月以合辑形式发表在HGT正刊中。
HGT的副主编、麻省大学医学院基因与细胞医学系主任高光坪教授是本届大会的主席之一，届时他将在大会现场与各位参会者开展深入交流。
摘要要求：
摘要全部使用英语，正文不超过250单词。
摘要格式请参照附件模板，包含标题、作者、作者单位、通讯作者邮箱、摘要正文、关键词。
摘要应只包含一个段落，简明扼要地说明研究目的、方法、主要发现及意义，请勿包含参考文献、表格或图片。
提交版本必须为Word文件，文件命名应与摘要英文标题保持一致。
文责自负，对于格式不符合要求、信息有误，或者不属于下述主题的摘要，将不予录用。
摘要主题：
基因治疗的基础和临床进展
递送系统
细胞疗法
免疫疗法
临床基因组编辑
小核酸疗法（包括RNAi）
临床试验（包括确证或阴性结果）
载体开发的改进
动物模型
评估基因和细胞疗法产品安全性的动物/体外临床前研究
临床方案
基因和细胞治疗产品的商业开发
如何提交：
点击下载摘要模板附件：Abstract Template for HRSC2026.docx
请根据模板附件完成摘要，并打开链接 https://lxi.me/27is8h 或扫描下方二维码提交（通过电脑/手机均可）。
